Coram's suit blames Caremark for termination of Lincare merger; seeks $1.5 bil.
This article was originally published in The Gray Sheet
Executive Summary
CORAM SUIT BLAMES CAREMARK FOR DISSOLUTION OF LINCARE MERGER, alleging that "the termination was the direct and proximate result" of Caremark's "actions and omissions...which caused Coram to incur losses and to become financially weakened." The Denver-based alternate site infusion company's suit estimates damages resulting from the loss of the merger with Lincare Holdings to be worth $500 mil.